.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC19_Satralizumab.Satralizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC19_Satralizumab.Satralizumab| name: | Satralizumab |
| ATC code: | L04AC19 | route: | subcutaneous |
| n-compartments | 2 |
Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. It is used as an immunosuppressive agent for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder. Satralizumab is approved for use in several countries and is administered to reduce relapse rates in NMOSD patients.
Pharmacokinetic parameters derived from adult patients with NMOSD administered subcutaneous satralizumab. Model corresponds to population PK analysis in clinical trials, mostly female, mean age approx. 42 years.
Leisegang, R, et al., & Plan, EL (2024). Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model. CPT: pharmacometrics & systems pharmacology 13(12) 2171–2184. DOI:10.1002/psp4.13230 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39380259